Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 24 April 2019

Indication(s)




Medicinal product no longer authorised



Eperzan is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control as:

Monotherapy
When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance.

Add-on combination therapy
In combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cardiovascular Metabolism Knowledge Centre

Cardiovascular Metabolism Knowledge Centre

The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.

Sleep Apnea

Sleep Apnea

Sleep apnea is a chronic condition characterised by recurrent interruptions in breathing throughout the sleep cycle. Learn about the two main types of sleep apnea and hear from experts as they present the latest research at the Sleep and Breathing conference (Marseille, 2019).

Cushing's Syndrome

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

+ 2 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/002735
Orphan designation No
Date First Approved 21-03-2014
Type Medicinal product subject to medical prescription
Marketing authorisation holder GlaxoSmithKline Trading Services Limited
Warnings

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reacti